Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions - a retrospective evaluation (FACTS)
Standard
Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions - a retrospective evaluation (FACTS). / Thaçi, Diamant; Weisenseel, Peter; Philipp, Sandra; Rosenbach, Thomas; Rotterdam, Sebastian; Augustin, Matthias; Neureither, Marcus; Reich, Kristian.
In: J DTSCH DERMATOL GES, Vol. 11, No. 5, 01.05.2013, p. 429-35.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions - a retrospective evaluation (FACTS)
AU - Thaçi, Diamant
AU - Weisenseel, Peter
AU - Philipp, Sandra
AU - Rosenbach, Thomas
AU - Rotterdam, Sebastian
AU - Augustin, Matthias
AU - Neureither, Marcus
AU - Reich, Kristian
N1 - © The Authors • Journal compilation © Blackwell Verlag GmbH, Berlin.
PY - 2013/5/1
Y1 - 2013/5/1
N2 - BACKGROUND: Safety and efficacy of fumaric acid esters (FAE) in patients with psoriasis requiring treated comorbidit condition were investigated.PATIENTS AND METHODS: Data collected from 7 dermatology centers were used for a retrospective analysis of patients treated continuously with FAE for at least 6 weeks who required at least one medication for a comorbid condition. The records were analyzed at baseline and after 1, 3, 6, 12 and 24 months of therapy. Safety parameters were monitored and the severity of skin symptoms was assessed by 'Physician's Global Assessment' (PGA).RESULTS: A total of 69 patients with moderate to severe psoriasis and a mean duration of 27.4 months of continuous treatment were included in the study. In less than 5% were interactions between FAE and co-medications observed. Changes of hepatic, renal or hematological laboratory parameters were usually insignificant and required a modification of FAE treatment in less than 12% of the cases. The percentage of patients documented as markedly improved or clear was 61% after 6 months, 77% after 12 months, and 75% after 24 months of therapy.CONCLUSIONS: In patients with moderate to severe psoriasis on co-medications, FAE were effective and safe without any noteworthy drug interactions.
AB - BACKGROUND: Safety and efficacy of fumaric acid esters (FAE) in patients with psoriasis requiring treated comorbidit condition were investigated.PATIENTS AND METHODS: Data collected from 7 dermatology centers were used for a retrospective analysis of patients treated continuously with FAE for at least 6 weeks who required at least one medication for a comorbid condition. The records were analyzed at baseline and after 1, 3, 6, 12 and 24 months of therapy. Safety parameters were monitored and the severity of skin symptoms was assessed by 'Physician's Global Assessment' (PGA).RESULTS: A total of 69 patients with moderate to severe psoriasis and a mean duration of 27.4 months of continuous treatment were included in the study. In less than 5% were interactions between FAE and co-medications observed. Changes of hepatic, renal or hematological laboratory parameters were usually insignificant and required a modification of FAE treatment in less than 12% of the cases. The percentage of patients documented as markedly improved or clear was 61% after 6 months, 77% after 12 months, and 75% after 24 months of therapy.CONCLUSIONS: In patients with moderate to severe psoriasis on co-medications, FAE were effective and safe without any noteworthy drug interactions.
KW - Cardiovascular Diseases
KW - Comorbidity
KW - Dermatologic Agents
KW - Drug-Related Side Effects and Adverse Reactions
KW - Female
KW - Fumarates
KW - Germany
KW - Humans
KW - Male
KW - Metabolic Diseases
KW - Middle Aged
KW - Prevalence
KW - Psoriasis
KW - Retrospective Studies
KW - Risk Assessment
KW - Treatment Outcome
U2 - 10.1111/ddg.12059
DO - 10.1111/ddg.12059
M3 - SCORING: Journal article
C2 - 23433431
VL - 11
SP - 429
EP - 435
JO - J DTSCH DERMATOL GES
JF - J DTSCH DERMATOL GES
SN - 1610-0379
IS - 5
ER -